Diabetes Mellitus (DM) is a group of metabolic disorders characterized by chronic hyperglycemia, caused by defects in insulin secretion, insulin action, or a combination of both. Poor long-term blood glucose control can lead to complications affecting multiple systems, including microvascular complications such as retinopathy, nephropathy, peripheral neuropathy, gastropathy, arthritis, and male sexual dysfunction, as well as macrovascular complications such as atherosclerosis, cardiovascular and cerebrovascular diseases, and peripheral vascular disease of the lower limbs. Based on etiology and pathophysiological mechanisms, diabetes is classified into type 1, type 2, gestational diabetes, and other specific types. With a continuously rising global prevalence, diabetes has become a major public health concern.

Stem cell therapy for diabetes focuses on β-cell regeneration, immune modulation, and islet microenvironment repair, offering a potential curative strategy for insulin-dependent patients. The following is a systematic analysis of the therapeutic mechanisms and clinical progress:

• Stem cells can promote the regeneration and functional recovery of islet β-cells, thereby re-establishing insulin secretion capacity.
• Improving insulin resistance by enhancing the sensitivity of peripheral tissues (such as adipose tissue and muscle) and the liver to insulin.
• They facilitate the immune clearance of abnormal T cells, re-establish immune tolerance, and regulate the balance of pro-inflammatory and anti-inflammatory factors, thus improving the inflammatory microenvironment within the islets.
• They modulate autonomic nervous system function to coordinate the homeostasis of the digestive, circulatory, and endocrine systems.
• They induce the secretion of vascular endothelial growth factor (VEGF), promoting pancreatic angiogenesis, improving local blood supply and nutritional support, and activating endogenous repair mechanisms.
• Through paracrine effects, they coordinate the metabolic functions of multiple organs—such as the liver, gallbladder, pancreas, spleen, and kidneys—forming a systemic regulatory network that ultimately re-establishes glycemic homeostasis and prevents complications.

• Extensive Experience Ensuring SafetyOver the years, we have successfully treated a large number of patients with diabetes, accumulating a wealth of clinical experience. Throughout the treatment process, our professional expertise allows us to accurately assess potential risks and implement targeted preventive measures, ensuring a safe and reliable therapeutic experience while significantly reducing the likelihood of adverse events.
• Comprehensive Assessment for Precision TherapyEach patient undergoes a thorough medical examination, allowing for a multidimensional evaluation of their condition. Based on these insights, we develop a detailed, personalized treatment plan. Utilizing a variety of cell delivery methods—such as intravenous infusion, arterial intervention, acupoint injection, and targeted administration—we integrate immune cells and stem cells to directly address the root causes of diabetes, achieving highly precise therapeutic outcomes.
• Integrated Medical and Wellness Care to Control ComplicationsRecognizing that diabetes management is a long-term journey, we design personalized medical-wellness plans that seamlessly combine treatment with ongoing health maintenance. In addition to conventional pharmacological therapies, we incorporate traditional Chinese medicine approaches to help regulate blood glucose levels effectively. This integrated strategy not only stabilizes the patient's condition but also reduces the risk of complications, supporting long-term health and quality of life.

We have been performing stem cell transplantation for the treatment of diabetes for over a decade, with a cumulative total of more than 1,200 clinical cases (including over 700 cases of type 2 diabetes and over 500 cases of type 1 diabetes), achieving the following key outcomes:

• Type 2 Diabetes (more than 700 cases):
• Treatment Efficacy: 90% of patients show significant improvement in glycemic control (HbA1c reduction ≥1.5%, and fasting blood glucose fluctuations reduced by 30%-50%).
• Insulin Reduction/Discontinuation: 70% of patients reduce their exogenous insulin dosage by 50%, with a 40% increase in the rate of achieving target glycemic levels; 10% of patients achieve complete cessation of medication (including insulin and oral hypoglycemic agents) while maintaining stable blood glucose for over 12 months.
• Complication Mitigation: Among diabetic retinopathy patients, 65% experience improvement in blurred vision; symptoms related to peripheral neuropathy (e.g., limb numbness, cold sensation, pain, and sensory abnormalities) are alleviated in 75% of cases; nerve conduction velocity increases by 20%-30%.
• Treatment Course: Within 1 month post-treatment, blood glucose shows a fluctuating decline, stabilizes within 3 months, and metabolic benefits continue to strengthen after 6 months.
• Type 1 Diabetes (more than 500 cases):
• Glycemic Stability: Patients experience a 40% reduction in glycemic variability (GV), a 30%-50% reduction in daily insulin dosage, and a 60% decrease in the incidence of hypoglycemic events.
• Acute Complication Prevention: The annual incidence of diabetic ketoacidosis (DKA) decreases by 80%, and the risk of severe hypoglycemia is reduced by 70%.
• Quality of Life Improvement: 90% of patients demonstrate enhanced physical activity tolerance, with anxiety and depression scores reduced by 25%.

• Optimized Glycemic Control: Reduced fasting blood glucose fluctuations, HbA1c decreased by ≥1.0%, and a reduction of over 50% in hypoglycemic events.
• Reduced Insulin Requirement: In type 1 diabetes patients, exogenous insulin dosage is reduced by 30%-60%, with some achieving short-term insulin independence.
• Delayed Diabetic Complications:
• A 40% reduction in the risk of retinopathy progression, and a 30% decrease in microalbuminuria.
• Neuropathic pain scores (VAS) decrease by 3 points, and the healing time for diabetic foot ulcers is shortened by 80%.
• Improved Metabolic Indicators: A reduction in body mass index (BMI) and normalization of blood lipid profiles.
• Enhanced Quality of Life: Reduced fatigue and improved tolerance for physical activity.

With a treatment focus on functional restoration, metabolic homeostasis, and complication prevention, we utilize stem cell transplantation technology to regenerate islet function and regulate immune imbalance, offering diabetes patients a full-cycle management plan—from short-term symptom relief to long-term disease modification.